N4P.LSE · N4 Pharma Plc

-

Please sign in to comment on N4P.LSE

1 Comment

Admin

4 years, 1 month ago

N4 Pharma Plc is currently in a long term uptrend where the price is trading 13.2% above its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

Its net income has dropped by 0.0% to $-162K since the same quarter in the previous year.

Finally, its free cash flow fell by 421.6% to $-475K since the same quarter in the previous year.

Based on the above factors, N4 Pharma Plc gets an overall score of 2/5.

Industry	Drug Manufacturers - Specialty & Generic
Exchange	LSE
CurrencyCode	GBP
ISIN	GB00BYW8QM32
Sector	Healthcare

Beta	0.66
Market Cap	3M
PE Ratio	None
Target Price	12
Dividend Yield	None

ABOUT

N4 Pharma Plc

N4 Pharma Plc, a specialist pharmaceutical company, develops silica nanoparticle delivery systems to enhance the cellular delivery of cancer treatments, gene therapy, and vaccines in the United Kingdom. It develops Nuvec, which offers silica nanoparticles with irregular surface structure and polyethyleneimine that traps and protects nucleic acid; and Liptide, a platform to deliver a proprietary siRNA sequence to silence a fibrotic gene for the treatment of glaucoma. The company was incorporated in 1979 and is based in London, the United Kingdom.

N4P.LSE · N4 Pharma Plc

-

N4 Pharma Plc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest N4 Pharma Plc using a moving average strategy